630125-91-6

Basic information

• Product Name: 4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline
• Synonyms: 4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline
• CAS NO: 630125-91-6
• Molecular Formula: C₁₄H₂₀F₃N₃
• Molecular Weight: 287.3239096
• Mol File: 630125-91-6.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 344.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.195±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.76±0.10(Predicted)
• CAS DataBase Reference: 4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline(630125-91-6)
• EPA Substance Registry System: 4-((4-ethylpiperazin-1-yl)Methyl)-3-(trifluoroMethyl)aniline(630125-91-6)

Safety Data

• Hazardous Substances Data: 630125-91-6(Hazardous Substances Data)

Usage

Uses

4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-benzenamine is one of the key reactants with N-[1-(4-Aminophenyl)-1H-pyrrolo[3,2-c]pyridin-4-yl]benzamide used in the synthesis of a pyrrolo[3,2-c]pyridine derivative [N-[1-[4-[[[[4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenyl]-1H-pyrrolo[3,2-c]pyridin-4-yl]benzamide (I)], an anticancer diarylurea derivative with multiple-kinase inhibitory effect; Also, it is an intermediate used in the synthesis of N-[4-[(4-Ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-N''-[4-[[6-(methylamino)-4-pyrimidinyl]oxy]phenyl]urea (E926495), which is an inhibitor of RET, FLT3, KDR, c-Abl and c-Kit. Also, it prevent the growth of human thyroid cancer cells.

Upstream product

• 859027-20-6 1-ethyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine 
• 630125-92-7 N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-2,2,2-trifluoro-acetamide 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 5308-25-8 4-ethylpiperazine 
• 876322-73-5 4-amino-2-(trifluoromethyl)benzaldehyde 
• 1609677-80-6 (4-amino-2-trifluoromethyl-phenyl)-(4-ethyl-piperazin-1-yl)-methanone 
• 65934-74-9 3-(trifluoromethyl)-4-methylaniline 
• 630125-84-7 N-(4-bromomethyl-3-trifluoromethylphenyl)-2,2,2-trifluoroacetamide 
• 350-96-9 2,2,2-trifluoro-N-(4-methylphenyl)acetamide 
• 393-06-6 4-amino-2-(trifluoromethyl)benzoic acid 

Downstream Products

• 872332-66-6 N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-nitrobenzamide 
• 1228451-30-6 ethyl 6-(3-(3-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)ureido)phenyl)-1H-indazole-3-carboxylate 
• 1232836-35-9 N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-3-iodo-4-methyl-benzamide 
• 1314863-30-3 1-(4-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(4-((4-ethylpiperazin-1-yl)methyl)-3-trifluoromethylphenyl)urea 
• 1315329-43-1 HG₆-64-1 
• 1334419-76-9 C₃₂H₃₃F₃N₆O₂ 
• 1334419-70-3 C₃₃H₃₅F₃N₆O₂ 
• 853299-52-2 1-[4-(2-aminopyrimidin-4-yloxy)phenyl]-3-[4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]urea 
• 630124-46-8 AST-487 
• 1609678-54-7 3-bromo-N-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-benzenesulfonamide 
• 1609679-16-4 1-[4-(4-ethyl-piperazin-1-yl methyl)-3-trifluoromethyl-phenyl]-3-(3-ethynyl-phenyl)-urea 
• 1609678-73-0 6-iodo-2,3-dihydro-indole-1-carboxylic acid [4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethylphenyl]-amide 
• 1609679-49-3 2-[2-amino-5-(3-{3-[4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl]-ureido}-phenylethynyl)pyrimidin-4-yl]-1-methyl-4-oxo-1,4,6,7-tetrahydro-pyrrolo[3,2-c]pyridine-5-carboxylic acid tert-butyl ester 

Relevant articles and documents

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties

Tumor-associated macrophages (TAMs) are predominantly associated with tumor growth. Colony-stimulating factor 1 receptor (CSF1R) acts as a key regulator of TAM survival and differentiation and is a molecular target for cancer therapies. Herein, novel CSF1

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.